GALNT6 and breast carcinoma: According to a previous study, the rate of bone marrow dissemination was 54.5% in GALNT6-positive patients, but only 4.3% in GALNT6-negative patients, suggesting that GALNT6 could be used as a biomarker of breast cancer metastasis [19].